What is Erste Group Bank’s Estimate for BMY FY2026 Earnings?

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Erste Group Bank raised their FY2026 earnings per share (EPS) estimates for Bristol Myers Squibb in a research note issued to investors on Wednesday, February 18th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings of $6.25 per share for the year, up from their prior forecast of $5.99. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Erste Group Bank also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $5.92 EPS.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

A number of other equities research analysts also recently commented on the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $57.00 price objective (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. HSBC reiterated a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $60.00 price objective (up previously from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Nine analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $60.19.

Bristol Myers Squibb Stock Up 0.6%

BMY stock opened at $60.66 on Monday. The firm has a market cap of $123.53 billion, a PE ratio of 17.58, a P/E/G ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $63.33. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm has a 50 day simple moving average of $56.22 and a 200 day simple moving average of $50.03.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were issued a dividend of $0.63 per share. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Norges Bank acquired a new position in Bristol Myers Squibb in the fourth quarter worth approximately $1,947,272,000. AQR Capital Management LLC grew its position in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Bristol Myers Squibb by 16.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after purchasing an additional 10,195,775 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Bristol Myers Squibb by 428.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after purchasing an additional 9,171,098 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after purchasing an additional 7,837,485 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.